TRAIL-R2 in the shadows: Epigenetic silencing and clinical implications in breast cancer
Oncotarget · 09.06.2026 · 17 (1) · 316-328
DOI: 10.18632/oncotarget.28891 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncotarget, erschienen am 09.06.2026. Verfasst von Nuzhat Khursheed und 12 weiteren Autor:innen. Hauptthemen laut MEDLINE: Breast Neoplasms, DNA Methylation, Receptors, TNF-Related Apoptosis-Inducing Ligand, Epigenesis, Genetic. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Zitieren
APA
Khursheed, N., Andrabi, S. I., Thakur, N., Qadir, Q., Ashraf, S., Farooq, A., Rashid, S., Jabeen, F., Khan, W. Y., Khursheed, A. U., Zargar, M. A., Asiaf, A., & Ganie, S. A. (2026). TRAIL-R2 in the shadows: Epigenetic silencing and clinical implications in breast cancer. Oncotarget, 17(1), 316-328. https://doi.org/10.18632/oncotarget.28891
Vancouver
Khursheed N, Andrabi SI, Thakur N, Qadir Q, Ashraf S, Farooq A, et al. TRAIL-R2 in the shadows: Epigenetic silencing and clinical implications in breast cancer. Oncotarget. 2026;17(1):316-328. doi:10.18632/oncotarget.28891
BibTeX
@article{Khursheed2026,
author = {Khursheed, Nuzhat and Andrabi, Syed Ishfa and Thakur, Natasha and Qadir, Quratul and Ashraf, Suhail and Farooq, Ambreena and Rashid, Safeena and Jabeen, Farhat and Khan, Waseen Younis and Khursheed, Allah-U-Deen and Zargar, Mohmmad Afzal and Asiaf, Asia and Ganie, Showkat Ahmad},
title = {TRAIL-R2 in the shadows: Epigenetic silencing and clinical implications in breast cancer},
journal = {Oncotarget},
year = {2026},
volume = {17},
number = {1},
pages = {316--328},
doi = {10.18632/oncotarget.28891}
}
EUVIMED